

Keloids - Pipeline Insight, 2021

<https://marketpublishers.com/r/KCE746A111C4EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: KCE746A111C4EN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Keloids - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Keloids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Keloids Understanding

Keloids: Overview

Keloids are raised overgrowths of scar tissue that occur at the site of a skin injury. They occur where trauma, surgery, blisters, vaccinations, acne or body piercing have injured the skin. Keloid scars tend to be larger than the original wound itself. They are shiny, smooth and rounded skin elevations that may be pink, purple, or brown. Most types of skin injury can contribute to keloid scarring. Keloids should not be confused with hypertrophic scars, which are raised scars that do not grow beyond the boundaries of the original wound and may reduce over time. A dermatologist diagnoses a keloid on the basis of its appearance and a history of tissue injury, such as surgery, acne or body piercing. Available treatments include: Removal with conventional surgery, Dressings, Corticosteroid injections, Compression, Cryosurgery, Radiation therapy, Laser therapy, and Fluorouracil injections.

'Keloids - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloids pipeline landscape is provided which includes the disease overview and Keloids treatment guidelines. The assessment part of the report embraces, in depth Keloids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Keloids R&D. The therapies under development are focused on novel approaches to treat/improve Keloids.

Keloids Emerging Drugs Chapters

This segment of the Keloids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Keloids Emerging Drugs

STP705: Sirnaomics

STP705 is a siRNA therapeutic comprising of two oligonucleotides with directly knock down of both TGF- β 1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA, including treatments of cholangiocarcinoma, nonmelanoma skin cancer, and hypertrophic scar. The drug is in Phase II clinical studies for the treatment of Keloids.

LEM-S401: Lemonex

LEM-S401 is a DegradaBALL-siRNA being developed to treat skin fibrosis. LEM-S401 down-regulates the expression of CTGF and downstream genes such as collagen types I and III, which are over-expressed in fibrotic tissues in vitro and in vivo. The drug is in preclinical studies for the treatment of Keloids.

Further product details are provided in the report.....

Keloids: Therapeutic Assessment

This segment of the report provides insights about the different Keloids drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Keloids

There are approx. 4+ key companies which are developing the therapies for Keloids. The companies which have their Keloids drug candidates in the most advanced stage, i.e. Phase II include, Sirnaomics.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Keloids pipeline report provides the therapeutic assessment of the pipeline drugs by the

Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Keloids: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Keloids therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloids drugs.

Keloids Report Insights

Keloids Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Keloids Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Keloids drugs?

How many Keloids drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Keloids?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Keloids therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Keloids and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Yuhan

Lemonex

BirchBioMed

Sirnaomics

Key Products

YH-siRNA1

LEM-S401

Kynurenic acid

STP705

Contents

- Introduction
- Executive Summary
- Keloids: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Keloids – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- Drug name: Company name
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- STP705: Sirnaomics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Early Stage Products (Phase I)
 - Comparative Analysis
- Drug name: Company name
 - Product Description
 - Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
 Comparative Analysis
LEM-S401: Lemonex
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report
Inactive Products
 Comparative Analysis
Keloids Key Companies
Keloids Key Products
Keloids- Unmet Needs
Keloids- Market Drivers and Barriers
Keloids- Future Perspectives and Conclusion
Keloids Analyst Views
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Keloids
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Keloids
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Keloids - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/KCE746A111C4EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/KCE746A111C4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970